Komiya Takefumi, Powell Emily, Takamori Shinkichi
Medical Oncology, Parkview Cancer Institute, Fort Wayne, Indiana.
Mirro Center for Research and Innovation, Parkview Research Center, Fort Wayne, Indiana.
JTO Clin Res Rep. 2020 Oct 20;2(3):100111. doi: 10.1016/j.jtocrr.2020.100111. eCollection 2021 Mar.
T components of the current eighth edition of lung cancer American Joint Commission on Cancer (AJCC) staging assignment include size of primary tumor and others such as chest wall invasion. The role of the presence of multiple T3 descriptors in prognosis remains unknown.
Using the National Cancer Database and the AJCC seventh edition, pathologically staged (R0) N0M0 NSCLC cases diagnosed in 2010 to 2016 were analyzed. The selected cases had primary size larger than 5 cm or staged as T3 by the AJCC seventh edition despite the size of less than 5 cm. T3 descriptor status according to the eighth edition was defined as single descriptor ("T3-single") with primary size of 5 to 7 cm or size less than 5 cm and T3 based on the seventh edition ("T3-other") or multiple descriptor ("T3-multi") with presence of both descriptors. Survival analysis was performed with validation of multivariate analyses.
Of the 108,632 surgically resected pathologically staged N0M0R0 NSCLC cases, 9931 met the following criteria: 8955 as T3-single (4381 as T3-size, 4574 as T3-other) and 884 as T3-multi. Univariate and multivariate analyses revealed that T3-multi had significantly worse overall survival than T3-single with a median survival of 37.3 versus 69.3 months, respectively. Propensity score matching analysis validated the statistical significance. Exploratory analysis also revealed that the survival of the T3-multi group is similar to that of the T4 groups.
Our retrospective analysis using the National Cancer Database suggests that prognosis of patients with multiple T3 descriptors is substantially worse than those with single descriptors. Further research may be required to accurately define the prognosis of NSCLC for future staging update.
美国癌症联合委员会(AJCC)第八版肺癌分期的T分类包括原发肿瘤大小以及其他因素,如胸壁侵犯。多个T3描述符的存在对预后的作用尚不清楚。
利用国家癌症数据库和AJCC第七版,分析2010年至2016年诊断的病理分期(R0)N0M0非小细胞肺癌(NSCLC)病例。所选病例的原发肿瘤大小大于5 cm,或尽管大小小于5 cm但根据AJCC第七版分期为T3。根据第八版,T3描述符状态定义为单个描述符(“T3-单一”),即原发肿瘤大小为5至7 cm或大小小于5 cm且根据第七版为T3(“T3-其他”),或多个描述符(“T3-多个”),即同时存在这两个描述符。进行生存分析并对多变量分析进行验证。
在108,632例手术切除的病理分期为N0M0R0的NSCLC病例中,9931例符合以下标准:8955例为T3-单一(4381例为T3-大小,4574例为T3-其他),884例为T3-多个。单变量和多变量分析显示,T3-多个的总生存期明显比T3-单一差,中位生存期分别为37.3个月和69.3个月。倾向评分匹配分析验证了统计学意义。探索性分析还显示,T3-多个组的生存期与T4组相似。
我们利用国家癌症数据库进行的回顾性分析表明,具有多个T3描述符的患者的预后明显比具有单个描述符的患者差。可能需要进一步研究以准确界定NSCLC的预后,以便未来更新分期。